Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Prostate Cancer Mortality: Groups Squabble Over ACS Forecast

Every January since 1951, the American Cancer Society (ACS) has published its report card on cancer, “Cancer Facts & Figures.” The... Read More

Prostate Cancer and Race

How much does infamous Tuskegee Experiment still loom over care for African Americans? Over the years, as a staff medical... Read More

High Anxiety with Active Surveillance in Prostate Cancer?

High anxiety with Active Surveillance in prostate cancer? not really. In my case, the first week after diagnosis was bad,... Read More

Novel Assay Can Guide Therapy in Advanced Prostate Cancer

A biochemical assay that can identify metastatic castration-resistant prostate cancer (mCRPC) patients best treated with either androgen receptor signaling (ARS)... Read More

Prostate Cancer Subtype that Responds to Immunotherapy Identified

Investigators from the U.S. and U.K. have identified a subtype of prostate cancer that may respond to immune checkpoint inhibitor... Read More

ASCO Supports New Options for Metastatic Prostate Cancer

Adding docetaxel or abiraterone (Zytiga) to conventional androgen deprivation therapy (ADT) significantly improved overall survival in men with newly diagnosed... Read More

No Survival Bump in Prostate Cancer with High-Dose RT

Higher-dose radiation therapy (RT) for localized prostate cancer did not improve overall survival despite reducing the frequency of biochemical failure... Read More

Longer Endocrine Tx Better in Prostate Cancer

Longer-duration androgen deprivation therapy (ADT) prevailed once again over briefer ADT for patients with high-risk nonmetastatic prostate cancer, whereas adding... Read More

Men Have Regret Years after Prostate Cancer Treatment

After years of introspection, about 15% of men with localized prostate cancer regretted the decisions they made regarding treatment, a... Read More

Risk Tool IDs Candidates for Adjuvant RT in Prostate Cancer

A novel risk stratification tool that combines pathologic tumor characteristics with data from the Decipher genomic classifier may help predict... Read More

1 2